Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without NeedlesU.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant to Advance Learnings from COVID-19CEPI grant aims to build on evidence of Micron Biomedical’s needle-free delivery of vaccines to bring CastleVax’s novel rapid-response platform to the clinic
Micron Biomedical Secures $43 Million in Total Grant Support to Improve Coverage of Measles and Rubella Vaccine and Accelerate World’s First Phase 2 Trial of Needle-Free Drug and Vaccine Technology in InfantsATLANTA, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced the company secured a $7.5 million grant from the Bill & Melinda Gates Foundation that brings total grant funding from the organization to $43 million.
